Insights

Clinical‑stage Enablement Euroscreen has advanced ESN364 into clinical development for Women’s Health Disorders, presenting an opportunity to position partner collaborations, contracted development, or sponsored studies around this lead program and to explore co-development or licensing deals to accelerate clinical milestones.

Small Molecule Focus With a strong track record in proprietary small molecules and a preclinical pipeline targeting GPCRs across neurodegeneration and inflammation, there are opportunities to package and co-develop multi-target discovery services or milestone-based collaborations for GPCR-focused partners.

Sustainability Edge Recent launches of PVC-free Xpert screen material highlight an environmental leadership angle that can be leveraged to attract pharma and contract research partners prioritizing sustainable supply chains and green lab practices in collaboration or sourcing discussions.

Financial Capacity Funding of 31 million and a revenue range of 1–10 million position Euroscreen as an active partner for grant-backed or milestone-driven partnerships, enabling discussions around co-financing, funded research, or staged collaboration agreements.

Investor & Collaboration Network Backed by notable investors such as Vesalius Biocapital, SRIW, and BNP Paribas Fortis Private Equity, Euroscreen offers potential for strategic alliances, co-development investments, and leverage of their investor network to accelerate partnerships in drug discovery and development.

Similar companies to Euroscreen sa

Euroscreen sa Tech Stack

Euroscreen sa uses 5 technology products and services including Sedo, Sedo Domain Parking, Google Fonts API, and more. Explore Euroscreen sa's tech stack below.

  • Sedo
    Domain Name Services
  • Sedo Domain Parking
    Domain Name Services
  • Google Fonts API
    Font Scripts
  • jQuery
    Javascript Libraries
  • Google Analytics
    Web Analytics

Euroscreen sa's Email Address Formats

Euroscreen sa uses at least 2 email formats:
Euroscreen sa Email FormatsExamplePercentage
FLast@euroscreen.comJDoe@euroscreen.com
91%
FMiddleLast@euroscreen.comJMichaelDoe@euroscreen.com
9%

Frequently Asked Questions

What is Euroscreen sa's official website and social media links?

Minus sign iconPlus sign icon
Euroscreen sa's official website is euroscreen.com and has social profiles on LinkedIn.

How much revenue does Euroscreen sa generate?

Minus sign iconPlus sign icon
As of July 2026, Euroscreen sa's annual revenue is estimated to be $1M - $10M.

What is Euroscreen sa's SIC code?

Minus sign iconPlus sign icon
Euroscreen sa's SIC code is 2834 - Pharmaceutical Preparations.

How many employees does Euroscreen sa have currently?

Minus sign iconPlus sign icon
As of July 2026, Euroscreen sa has approximately 11 employees across 2 continents, including North America and Europe. Key team members include Executive Assistant: N. W. Explore Euroscreen sa's employee directory with LeadIQ.

What industry does Euroscreen sa belong to?

Minus sign iconPlus sign icon
Euroscreen sa operates in the Pharmaceuticals industry.

What technology does Euroscreen sa use?

Minus sign iconPlus sign icon
Euroscreen sa's tech stack includes Sedo, Sedo Domain Parking, Google Fonts API, jQuery and Google Analytics.

What is Euroscreen sa's email format?

Minus sign iconPlus sign icon
Euroscreen sa's email format typically follows the pattern of FLast@euroscreen.com. Find more Euroscreen sa email formats with LeadIQ.

How much funding has Euroscreen sa raised to date?

Minus sign iconPlus sign icon
As of July 2026, Euroscreen sa has raised $31M in funding. The last funding round occurred on Oct 02, 2015.
Euroscreen sa logo

Euroscreen sa

PharmaceuticalsWallonia, Belgium11-50 Employees

Euroscreen S.A. is a privately held drug discovery and development company based in Gosselies, in the Wallonia region of Belgium. It concentrates on identifying and advancing first-in-class small molecule drug candidates to address unmet medical needs. The company has a track record of innovative proprietary molecules and has advanced its lead program ESN364 for women's health disorders into clinical development, with oral availability and high specificity. In addition to ESN364, Euroscreen pursues other small molecules in preclinical stages that target G-protein coupled receptors across therapeutic areas such as neurodegenerative diseases and inflammation.

Recent updates describe the launch of Xpert screen material, noted as PVC-free and manufactured without hazard substances.

Section iconCompany Overview

SIC Code
2834 - Pharmaceutical Preparations
Employees
11-50

Section iconFunding & Financials

  • $31M

    Euroscreen sa has raised a total of $31M of funding over 2 rounds. Their latest funding round was raised on Oct 02, 2015 as a Series B.

  • $1M - $10M

    Euroscreen sa's revenue is estimated to be in the range of $1M - $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.